Anastasios Pappas, MD
Dermatology · Saint Paul, MNNPI 1912904970
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,750 of the $2,408 with a category attached, or 72.7%. Johnson & Johnson accounts for 73.7% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $2,077, more than ten times the $52 reported in 2019.
Across 32 payments — averaging $75.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Axsome Therapeutics, Inc.$121
- LEO Pharma Inc.$88
- Regeneron Healthcare Solutions, Inc.$85
- Sanofi$64
- Lilly USA, LLC$58
- plus $217 from 13 others
What the payments were for
- Consulting fees$1,75073%
- Food & beverage$61626%
- Education$432%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $1,775 |
| Axsome Therapeutics, Inc. | 1 | $121 |
| LEO Pharma Inc. | 4 | $88 |
| Regeneron Healthcare Solutions, Inc. | 5 | $85 |
| Sanofi | 3 | $64 |
| Lilly USA, LLC | 3 | $58 |
| Mimedx Group, Inc. | 1 | $28 |
| Biowound Solutions, Inc. | 1 | $22 |
| Stimlabs LLC | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $19 |
| Reprise Biomedical, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
| Kerecis Limited | 1 | $15 |
| Dermavant Sciences, Inc. | 1 | $15 |
| Organogenesis Inc. | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Biofrontera Inc. | 1 | $14 |
| Incyte Corporation | 1 | $13 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,408 in reported general payments places this provider in the 85th percentile of 273 dermatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 29 | $326,692 |
| OtezlaApremilast | 11 | $53,949 |
| Dupixent SyringeDupilumab | 13 | $48,045 |
| Fluorouracil | 147 | $10,456 |
| MethotrexateMethotrexate Sodium | 140 | $3,658 |
| Clobetasol Propionate | 79 | $3,354 |
| Metronidazole | 51 | $2,992 |
| Doxycycline Hyclate | 57 | $2,935 |
| Ketoconazole | 125 | $2,330 |
| Acitretin | 17 | $2,313 |
| Finasteride | 225 | $2,287 |
| Minocycline Hcl | 26 | $2,164 |
| Tacrolimus | 16 | $2,133 |
| Calcipotriene | 14 | $2,083 |
| Doxycycline Monohydrate | 47 | $1,637 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Saint Paul
- Todd SeelhammerSaint Paul$63K
- Jessica HealySaint Paul$1K
- Kristina ShafferEagan$538K
- Margareth Pierre-LouisMinneapolis$439K
- Maria HordinskyMinneapolis$85K
- Afsaneh AlaviRochester$71K
- Brittney SchultzMinneapolis$52K
- David PearsonMinneapolis$46K
- Phillip EckerWayzata$31K
- Noah GoldfarbMinneapolis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.